PARSIPPANY, N.J., June 28 /PRNewswire/ -- Preliminary results of a pre-specified subgroup study analysis of patients with diabetes and hypertension demonstrated that the investigational triple combination therapy of olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) resulted in a statistically significant greater Least Squares (LS) mean reduction in blood pressure from baseline at week 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P less than or equal to 0.0013) as compared to corresponding dual combination therapy [olmesartan medoxomil (40 mg) / amlodipine (10 mg); olmesartan medoxomil (40 mg) / hydrochlorothiazide (25 mg); or amlodipine (10 mg) and hydrochlorothiazide (25 mg)].(1) Blood pressure is more difficult to control among patients with hypertension and diabetes compared to patients with hypertension alone.(2) These findings were presented today during a poster presentation at the American Diabetes Association (ADA) 70th Annual Scientific Sessions in Orlando, FL.
This analysis of the TRINITY study (Triple Therapy with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hypertensive Patients Study) also demonstrated that the investigational triple combination therapy (40/10/25 mg) enabled more patients with hypertension and diabetes to achieve blood pressure goal of <130/80 mm Hg at week 12 as compared to corresponding dual combination therapies (41.1 percent in the triple combination group versus 10.1 to 16.3 percent in the dual combination groups, P less than or equal to 0.0002).(1) Baseline blood pressures for those patients receiving the triple combination therapy and corresponding dual combination therapies were 170.7/98.3 mm Hg and 170.7-173.1/97.8-99.3 mm Hg, respectively.(1)